Beranda › Kanker Laring
Uji klinis Kanker Laring yang merekrut di AS
26 studi untuk Kanker Laring merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Milwaukee, WI8 studi
- Atlanta, GA8 studi
- Chicago, IL8 studi
- Kansas City, MO7 studi
- St. Louis, MO7 studi
- Edison, NJ6 studi
- Pittsburgh, PA6 studi
- Durham, NC6 studi
- Portland, OR6 studi
- Baltimore, MD6 studi
- Cincinnati, OH6 studi
- Richmond, VA6 studi
- New York City, NY5 studi
- Queens, NY5 studi
- Kansas City, KS5 studi
- Naperville, IL5 studi
- Omaha, NE5 studi
- Philadelphia, PA5 studi
- Oklahoma City, OK5 studi
- Ann Arbor, MI5 studi
- Champaign, IL5 studi
- Charleston, IL5 studi
- Danville, IL5 studi
- Overland Park, KS5 studi
- Irvine, CA5 studi
- Cedar Rapids, IA5 studi
- Duluth, MN5 studi
- Fargo, ND5 studi
- Lansing, MI5 studi
- Stevens Point, WI5 studi
- Joliet, IL5 studi
- Peoria, IL5 studi
- Bloomington, IL5 studi
- Wausau, WI5 studi
- Cape Girardeau, MO5 studi
- O'Fallon, MO4 studi
- Erie, PA4 studi
- Des Moines, IA4 studi
- Los Angeles, CA4 studi
- Little Rock, AR4 studi
Berdasarkan negara bagian
- Arizona5 studi
- Arkansas5 studi
- California9 studi
- Colorado7 studi
- Connecticut3 studi
- Delaware3 studi
- Florida8 studi
- Georgia8 studi
- Idaho4 studi
- Illinois9 studi
- Indiana4 studi
- Iowa8 studi
- Kansas7 studi
- Kentucky3 studi
- Louisiana4 studi
- Maryland7 studi
- Massachusetts7 studi
- Michigan6 studi
- Minnesota7 studi
- Mississippi3 studi
- Missouri9 studi
- Montana5 studi
- Nebraska5 studi
- New Hampshire3 studi
- New Jersey7 studi
- New Mexico3 studi
- New York10 studi
- North Carolina8 studi
- North Dakota5 studi
- Ohio11 studi
- Oklahoma6 studi
- Oregon6 studi
- Pennsylvania9 studi
- South Carolina5 studi
- South Dakota3 studi
- Tennessee3 studi
- Texas5 studi
- Virginia7 studi
- Washington3 studi
- Wisconsin9 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06589804Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06997068Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07195734BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05136196Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06980038Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT05172245Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT02734537Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07156227Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT06532279Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT07441681Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Jul 2026 · NCT06662058Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Jul 2026 · NCT01365169Integrated Cancer Repository for Cancer Research
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 19 hingga 110 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT02012699Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Apr 2026 · NCT07209189Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Apr 2026 · NCT03010150TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Mar 2026 · NCT06868433A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Feb 2026 · NCT07063212Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Feb 2026 · NCT06636734Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Feb 2026 · NCT01473784CONFIRM: Magnetic Resonance Guided Radiation Therapy
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Feb 2026 · NCT04368702Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Des 2025 · NCT05793151Phase II Randomized Study of Hypofractionated Versus Conventional Radiotherapy
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Nov 2025 · NCT06080503SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer
Menerima pesertaFase awal 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Okt 2025 · NCT06914999Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
Menerima pesertaStudi observasional
Usia 21 hingga 90 · Semua jenis kelamin · Diperbarui 22 Sep 2025 · NCT00900419Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.